David Putman PhD

David Putman, Ph.D. is the Chief Operating Officer of Anvyl LLC. Dr. Putman has more than 17 years of pharmaceutical industrial experience in large and small companies. He has diverse experience as a scientist, group leader, program leader and manager, holding positions at Syntex, Roche, UCB, Kadmus and Xytis. Several of the programs Dr. Putman has led or in which he has participated are now in clinical development.

Most recently, while serving as the VP of chemistry at Kadmus Pharmaceuticals, he led the Fatty Acid Amide Hydrolase inhibitor program, which was purchased by Organon (now Merck), and (as Director of Chemistry) was part of the scientific and management teams at Xytis, discovering and developing the first known Type-I allosteric modulator of a7 nicotinic ion channel. He has more than thirty publications and patents, and has contributed to several books.